BACKGROUND: Chronic heart failure (CHF) is a progressive process requiring complex therapeutic interventions. Recently, several trials documented the clinical improvement and regression of left ventricular (LV) remodeling and function in patients on optimized CHF treatment. Furthermore, some authors reported isolated cases of patients who apparently "healed" from CHF. The aim of the present study was to characterize the phenomenon of the normalization in clinical status and LV size and function in CHF patients. METHODS AND RESULTS: We monitored the clinical and echocardiographic parameters of a large cohort of patients with CHF and LV ejection fraction <40% every 6 months for a mean period of 17 +/- 9 months. Twenty of 110 study patients (18%) normalized clinical status and LV size and ejection fraction at any time (mean time 13 +/- 6 months) during the follow up. Such condition, however, was subsequently lost in 11 patients. The normalization was predicted by the nonischemic etiology of CHF, arterial hypertension, absence of diabetes mellitus, carvedilol therapy, and the dose of carvedilol. CONCLUSIONS: The normalization in clinical status and LV size and function is not infrequently observed in patients on optimal CHF therapy. It is predicted by a set of clinical variables and favored by beta-blocker therapy. At medium term, this condition fades in a significant portion of patients.
BACKGROUND:Chronic heart failure (CHF) is a progressive process requiring complex therapeutic interventions. Recently, several trials documented the clinical improvement and regression of left ventricular (LV) remodeling and function in patients on optimized CHF treatment. Furthermore, some authors reported isolated cases of patients who apparently "healed" from CHF. The aim of the present study was to characterize the phenomenon of the normalization in clinical status and LV size and function in CHFpatients. METHODS AND RESULTS: We monitored the clinical and echocardiographic parameters of a large cohort of patients with CHF and LV ejection fraction <40% every 6 months for a mean period of 17 +/- 9 months. Twenty of 110 study patients (18%) normalized clinical status and LV size and ejection fraction at any time (mean time 13 +/- 6 months) during the follow up. Such condition, however, was subsequently lost in 11 patients. The normalization was predicted by the nonischemic etiology of CHF, arterial hypertension, absence of diabetes mellitus, carvedilol therapy, and the dose of carvedilol. CONCLUSIONS: The normalization in clinical status and LV size and function is not infrequently observed in patients on optimal CHF therapy. It is predicted by a set of clinical variables and favored by beta-blocker therapy. At medium term, this condition fades in a significant portion of patients.
Authors: Luigi Adamo; Andrew Perry; Eric Novak; Majesh Makan; Brian R Lindman; Douglas L Mann Journal: Circ Heart Fail Date: 2017-06 Impact factor: 8.790
Authors: Marco Merlo; Marco Masè; Andrew Perry; Eluisa La Franca; Elena Deych; Laura Ajello; Diego Bellavia; Andrea Boscutti; Marco Gobbo; Giuseppe Romano; Davide Stolfo; John Gorcsan; Francesco Clemenza; Gianfranco Sinagra; Luigi Adamo Journal: Heart Date: 2021-09-07 Impact factor: 5.994
Authors: José Rosino de Araújo Rocha Reis Filho; Juliano Novaes Cardoso; Cristina Martins dos Reis Cardoso; Antonio Carlos Pereira-Barretto Journal: Arq Bras Cardiol Date: 2015-03-27 Impact factor: 2.000
Authors: Andrew Perry; Francis Loh; Luigi Adamo; Kathleen W Zhang; Elena Deych; Randi Foraker; Douglas L Mann Journal: PLoS One Date: 2021-03-18 Impact factor: 3.240